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ABSTRACT Primary effusion lymphoma (PEL) is a lymphogenic disorder associated
with Kaposi’s sarcoma-associated herpesvirus (KSHV) infection. Key to the survival
and proliferation of PEL is the canonical NF-B pathway, which becomes constitu-
tively activated following overexpression of the viral oncoprotein KSHV vFLIP (ks-
vFLIP). This arises from its capacity to form a complex with the modulatory subunit
of the IB kinase (IKK) kinase, IKK (or NEMO), resulting in the overproduction of
proteins that promote cellular survival and prevent apoptosis, both of which are im-
portant drivers of tumorigenesis. Using a combination of cell-based and biophysical
assays together with structural techniques, we showed that the observed resistance
to cell death is largely independent of autophagy or major death receptor signaling
pathways and demonstrated that direct targeting of the ks-vFLIP–IKK interaction
both in cells and in vitro can be achieved using IKK-mimetic peptides. Our results
further reveal that these peptides not only induce cell killing but also potently sensi-
tize PEL to the proapoptotic agents tumor necrosis factor alpha and etoposide and
are the ﬁrst to conﬁrm ks-vFLIP as a tractable target for the treatment of PEL and re-
lated disorders.
IMPORTANCE KSHV vFLIP (ks-vFLIP) has been shown to have a crucial role in cellu-
lar transformation, in which it is vital for the survival and proliferation of primary ef-
fusion lymphoma (PEL), an aggressive malignancy associated with infection that is
resistant to the majority of chemotherapeutic drugs. It operates via subversion of
the canonical NF-B pathway, which requires a physical interaction between ks-vFLIP
and the IKK kinase modulatory subunit IKK. While this interaction has been directly
linked to protection against apoptosis, it is unclear whether the suppression of other
cell death pathways implicated in ks-vFLIP pathogenesis is an additional contributor.
We demonstrate that the interaction between ks-vFLIP and IKK is pivotal in confer-
ring resistance to apoptosis. Additionally, we show that the ks-vFLIP–IKK complex
can be disrupted using peptides leading to direct killing and the sensitization of PEL
cells to proapoptotic agents. Our studies thus provide a framework for future thera-
peutic interventions.
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Kaposi’s sarcoma-associated herpesvirus (KSHV) is the most common cause ofmalignancy among AIDS patients (1, 2). In addition to being the main etiological
agent of Kaposi’s sarcoma (KS), KSHV infection has also been linked to primary effusion
lymphoma (PEL) and multicentric Castleman’s disease (3, 4). While AIDS-KS can be
successfully treated with antiretroviral drugs at the early stages of onset, there are to
date no highly effective treatments for the advanced disease or associated lymphopro-
liferative disorders. In particular, PEL has an extremely poor prognosis for which
average survival rates vary between 3 and 6 months following diagnosis, prompting an
urgent need for the identiﬁcation of novel drug targets and therapeutics. During the
latent phase of infection, KSHV produces a limited number of viral proteins that are
essential for subverting the host to promote survival, immune evasion, viral replication,
and propagation (5). One such protein is KSHV vFLIP (ks-vFLIP), a cellular FLIP homo-
logue that targets the canonical and alternative NF-B transcriptional pathways, ren-
dering them constitutively active (6, 7). This persistent activation results in the dereg-
ulated overexpression of gene products known to promote cellular survival and inhibit
apoptosis, both of which have been strongly implicated in transformation. It has also
been demonstrated that ks-vFLIP is crucial for the proliferation of PEL (8, 9), promoting
anchorage-independent survival of endothelial cells (10) while suppressing autophagy
(11) and death receptor signaling (8, 12).
Although persistent activation of both the canonical and alternative NF-B path-
ways by KSHV have been documented, its effects on the canonical pathway have been
the most extensively characterized. Key to activation are the p65(RelA)/p50 or p65/c-Rel
heterodimeric transcription factors (13–15). These are normally sequestered in the
cytoplasm as a consequence of their associations with the IB family of inhibitory
proteins that occlude their nuclear localization sequences, thus preventing transit to
the nucleus. On activation, the IB proteins are targeted for degradation by the 26S
proteosome following phosphorylation and subsequent K48-linked ubiquitination. This
culminates in the liberated transcription factors being able to enter the nucleus and
initiate transcription of the various genes under their control. Central to this process is
the IB kinase (IKK) kinase complex or signalosome (16) that instigates the initial
phosphorylation of the IB proteins. The core IKK complex consists of the kinase
subunits IKK and IKK together with the essential modulatory element IKK (also
referred to as NEMO), which is the target for ks-vFLIP. By means of a physical interaction
with IKK, ks-vFLIP is able to “lock” the IKK kinase complex into a persistently phos-
phorylated state via a mechanism that appears to be independent of known upstream
cellular activators, such as Traf2, Traf3, Traf6, LUBAC, Tak-1, and HOIL-1 (17), and is thus
distinct to those resulting from stimulation by endogenous proinﬂammatory cytokines
or cellular FLIP variants (18).
In previous studies, the crystal structure of ks-vFLIP bound to IKK (PDB code 3CL3)
was determined (19). Pivotal to complex formation are amino acids within the region
of IKK spanning residues 230 to 248 (a dimeric coiled-coil) that are accommodated
within two clefts of a ks-vFLIP monomer. Signiﬁcantly, disruption of important inter-
acting residues within this sequence using site-directed mutagenesis has been shown
to drastically reduce the levels of NF-B activation. Here we report that a conforma-
tionally constrained, stapled peptide based on this interacting motif (spIKK) and an
analogous glutathione S-transferase (GST)-peptide fusion protein (GST-IKK) not only
are competitive inhibitors of IKK in vitro but also, when combined with etoposide
(ETO) or tumor necrosis factor alpha (TNF-), drastically reduce the viability of BC3 and
BCP-1 cells. This is a direct consequence of removing the apoptotic block imposed by
the ks-vFLIP-mediated overproduction of prosurvival/antiapoptotic proteins, in which
there appears to be little coinvolvement of ATG3-dependent autophagic and no
involvement of important death receptor-mediated pathways. Our ﬁndings not only
demonstrate ks-vFLIP as an amenable target for the treatment of PEL and other
KSHV-related malignancies using gene therapies but also suggest that stapled pep-
tides/helical mimetics could form a basis for the design of future high-potency thera-
peutics.
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RESULTS
The antiapoptotic effects of ks-vFLIP overexpression are largely independent
of autophagic and key death receptor signaling pathways. Although it has been
established that dysregulated activation of the canonical NF-B pathway by ks-vFLIP
renders mouse embryonic ﬁbroblasts resistant to apoptosis induced by TNF- (12), we
sought to ascertain whether ks-vFLIP expression also prevents cell death induced by
ETO. Unlike TNF-, which instigates death receptor signaling, ETO, a topoisomerase II
inhibitor, initiates cell death through the generation of DNA double-strand breaks (20).
Our results revealed that at the highest concentration of ETO used (50 M), the survival
of Jurkat cells was only moderately reduced compared to that of cells null for ks-vFLIP,
which were severely compromised (Fig. 1A). The results with ETO closely mirror the
trend observed for those treated with TNF- (Fig. 1B) and were consistent with those
of Tolani et al. (12), thus conﬁrming ks-vFLIP as a key factor in the inhibition of
apoptosis able to override the effects of both ETO and TNF-. We next investigated the
potential involvement of death-inducing signaling complex (DISC) formation and au-
FIG 1 Antiapoptotic effects of ks-vFLIP overexpression in Jurkat cells. Viability assays were conducted with
Jurkat cells treated with various concentrations of ETO (A) and TNF- (B). The ability of ks-vFLIP to protect
Jurkat cells against the effects of ETO (C) and TNF- (D) where FADD and ATG3 have been silenced using
siRNA, together with those null for IKK, was assessed. (E) (Left image) Immunoblot comparing ks-vFLIP
levels in Jurkat vFLIP cells with those in the KSHV-transformed PEL cell line BC3. (Right and middle images)
Downregulation of FADD and ATG3 in Jurkat cells using siRNA. Asterisks indicate signiﬁcant differences (*,
P  0.05, **, P  0.01, ***, P  0.001; z test). ns, not signiﬁcant.
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tophagy since ks-vFLIP has been cited (somewhat controversially) to interact with
procaspase 8, an effector caspase whose activation requires the adaptor protein FADD
(21), and to physically associate with the ubiquitin-like conjugating enzyme ATG3,
which is essential for the formation of autophagosomes (11). Viability assays were
therefore conducted using Jurkat cells in which FADD and ATG3 were silenced (using
small interfering RNA [siRNA]) together with those null for IKK in the presence of both
ETO and TNF- (Fig. 1C and D). Figure 1E shows that the level of expression of ks-vFLIP
in the engineered Jurkat cells is 3- to 5-fold greater than observed in the KSHV-
transformed PEL cell line BC3 and that both FADD and ATG3 are undetectable by
immunoblotting in those treated with siRNA. While cell survival was severely compro-
mised in all three scenarios, it could to a large extent be rescued in the FADD/ATG3
siRNA Jurkat cells overexpressing wild-type (WT) ks-vFLIP, although to a lesser degree
in the case of ATG3 and ETO. Only cells null for IKK were completely refractory to the
protective effects of ks-vFLIP. Furthermore, the A57L ks-vFLIP mutant, which has been
shown to disrupt IKK binding (19), could not protect cells against apoptosis induced
by ETO or TNF- (Fig. 1C and D), highlighting the importance of the ks-vFLIP–IKK
interaction.
Targeting the ks-vFLIP–IKK interaction and design of the IKK stapled pep-
tide spIKK. Having ascertained that neither DISC formation or autophagy is a major
factor in conferring ks-vFLIP-induced resistance to apoptosis, we next investigated
whether the ks-vFLIP–IKK interaction, shown to be essential, could be successfully
disrupted by mimetic peptides in vitro. The original ks-vFLIP–IKK structure (PDB code
3CL3) adopts a heterotetrameric conﬁguration in which a ks-vFLIP dimer associates
with IKK in a dimeric, parallel, helical coiled-coil conformation (Fig. 2A). Although
complex formation involves two distinct regions of ks-vFLIP (cleft 1 and cleft 2)
simultaneously bound to each IKK monomer in the dimeric assembly (Fig. 2A), it was
shown that the protein-protein interactions mediated by cleft 1 are crucial (19). We
therefore sought to establish whether IKK binding to ks-vFLIP could be mimicked by
single peptides incorporating residues shown to mediate important cleft 1 interactions.
To achieve this, an unmodiﬁed 30-mer peptide (residues 224 to 253) was designed to
encompass the interacting motif and neighboring residues along with a 21-mer (resi-
dues 226 to 248), only marginally longer than the motif itself (residues 230 to 248 [Fig.
2B]). These were commercially synthesized and their ability to associate with ks-vFLIP
was assessed using a thermoﬂuor assay (Fig. 2C and D). While neither the 21- or 30-mer
peptide could emulate the 8°C shifts in melting temperature observed with the IKK
fragment encompassing residues 150 to 272 [IKK(150–272)] used in the original
structural studies at a concentration of 30 M (contributions from denaturation of the
IKK dimer being insigniﬁcant owing to its lack of a substantial hydrophobic core [Fig.
2C]), both gave rise to shifts of 4°C at 100 M despite being of signiﬁcantly different
lengths. These results were the ﬁrst indication that ks-vFLIP could be targeted using
single peptides centered on the minimal interacting motif.
The fact that we were able to at least partially substitute IKK for unmodiﬁed
peptides led us to investigate whether the IKK ks-vFLIP minimal interacting motif
could be engineered into a conformationally constrained, helical peptide through
incorporation of an appropriate aliphatic linker or “staple” (22). This strategy has been
successfully used in several distinct systems involving protein-protein interactions
mediated through helical recognition (23–26). It relies on the premise that one of the
interacting partners can be simulated by a helical peptide resulting from the replace-
ment of two nonessential amino acids by (S)-2-(2= pentenyl)alanine that are subse-
quently cyclized to produce a constraining aliphatic linker. Such peptides have been
frequently found to have enhanced afﬁnity for their targets as well as innate cell
permeability, thought to partially derive from the hydrophobic nature of the linker and
favored by an overall net positive charge.
Inspection of the ks-vFLIP–IKK structure identiﬁed Q236 and E240 as potential sites
on IKK for an i, i  4 staple given that they are nonessential (Fig. 3A). To test our
rationale in silico, a model peptide was constructed of the IKK minimal interacting
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FIG 2 vFLIP-IKK interaction and peptide thermoﬂuor analysis. (A) (Left) Cartoon depiction of the ks-vFLIP–IKK heterotetramic complex (PDB code 3CL3). The
IKK and ks-vFLIP monomers are shown in gray and wheat, respectively. (Right) The ks-vFLIP-IKK dimer interface highlighting cleft 1 (white) and cleft 2 (cyan).
Residues essential for the formation of the cleft 1 interactions (H235, F238, D242, and K246) are colored magenta, and those that interact with cleft 2 (Q236
and E240) are colored blue. (B) IKK ks-vFLIP minimal interacting motif (residues 230 to 248) together with those forming the 30- and 21-mer peptides (pink
and violet, respectively) used in the thermoﬂuor studies. (C) Thermal denaturation proﬁles for ks-vFLIP (left) and IKK (right) at various concentrations. The lack
of a signiﬁcant response over the range of concentrations tested for IKK is owing to its dimeric coiled conﬁguration that lacks a substantial hydrophobic core.
(D) Thermal denaturation of ks-vFLIP in the presence of various concentrations of IKK (left) and the 21-mer (pink) and 30-mer (violet) (right) peptides.
KSHV Resistance to Apoptosis Blocked by Peptides Journal of Virology
December 2017 Volume 91 Issue 23 e01170-17 jvi.asm.org 5
 o
n
 N
ovem
ber 14, 2017 by BIRKBECK CO
LLEG
E
http://jvi.asm.org/
D
ow
nloaded from
 
motif (L230 to S248) incorporating the staple and energy minimized (MMFF94x force
ﬁeld) using the Molecular Operating Environment (MOE) software package (2014.09;
Chemical Computing Group Inc., Montreal, QC, Canada). Following minimization, the
helical geometry and overall conﬁguration of the peptide were observed to remain
unchanged. The model was then docked into cleft 1 of ks-vFLIP and the complex
subjected to energy minimization in which the position of the protein moiety was ﬁxed
while permitting movement of the peptide. The resulting energy-minimized complex
revealed that all of the important interactions remained unperturbed. Based on these
FIG 3 spIKK and the crystal structure of the GB1–ks-vFLIP–spIKK complex. (A) (Left) Sequence of the in silico-designed
IKK-mimetic peptide (spIKK), together with the position and structure of (S)-2-(2= pentenyl)alanine used to replace Q236 and
E240 (green). The key cleft 1 binding residues are depicted in magenta. (Right) Energy-minimized model of spIKK highlighting
the aliphatic linker (green) after cyclization and its position relative to the cleft 1 binding residues on the opposite face of the
helix. (B) (Left) Reﬁned coordinates of spIKK superimposed on the initial 2mFo-DFc electron density map (blue, contoured at
1), calculated using the coordinates of ks-vFLIP from PDB entry 3CL3 alone after molecular replacement. (Right) 2mFo-DFc
(blue, contoured at 1) and mFo-DFc (green, contoured at 3) electron densities associated with the C-terminal cysteine of
one spIKK peptide. (C) (Left) ks-vFLIP–spIKK dimer interface (for clarity, one IKK monomer is depicted as a cartoon [light
gray]). The cleft 1 interactions (magenta for spIKK and yellow-orange for cleft 1 in ks-vFLIP) are entirely conserved. The
aliphatic staple (green), though partially ordered, projects into the cavity between cleft 1 and cleft 2 (cyan) of the opposite
ks-vFLIP monomer alongside F53. (Right) spIKK-spIKK dimer (gray) superimposed on the analogous interface in the
ks-vFLIP-IKK(150–272) complex (pink) shows an almost identical conﬁguration and arrangement of residues.
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ﬁndings, the modiﬁed peptide (spIKK [Fig. 3A]) was subsequently synthesized with an
added C-terminal cysteine to permit future conjugation to cell transporter molecules or
ﬂuorophores. Inclusion of this nonnative residue had no effect on the protein-peptide
interactions as initially judged by in silico modeling and later conﬁrmed by in vitro
studies (see below).
spIKK is an effective mimetic of IKK. Our focus on a single peptide together
with the presence of the aliphatic staple made it difﬁcult to predict the exact nature of
a ks-vFLIP–spIKK complex and, in particular, its stoichiometry. To address this, we
cocrystallized ks-vFLIP with spIKK. Similar to the ks-vFLIP–IKK heterotetramic com-
plex (PDB code 3CL3), two molecules of GB1–ks-vFLIP were seen to comprise the
asymmetric unit, where further analysis revealed clear electron density for peptides
bound to each ks-vFLIP monomer (Fig. 3B). Unexpectedly, sizeable density associated
with the C-terminal cysteines of the two peptides could also be identiﬁed. Based on size
and overall shape, it is likely to originate from the vitamin B12 additive, but owing to
disorder, it could not be unambiguously modeled for either monomer (Fig. 3B).
The overall conﬁguration of the ks-vFLIP–spIKK complex revealed a heterotetra-
meric arrangement analogous to that observed in the ks-vFLIP-IKK(150–272) struc-
ture, where both peptides contacted clefts 1 and 2 (Fig. 3C). As indicated by our
modeling studies, the ks-vFLIP–spIKK binding interface mediated by cleft 1 showed a
high degree of structural similarity to the original ks-vFLIP–IKK(150–272) crystal
structure. Crucially, the H235, F238, E242, and K246 quartet, central to binding and
subsequent NF-B activation, form similar contacts with the cleft 1 region in the
peptide complex. Also in common with the ks-vFLIP–IKK(150–272) heterotetramer,
there were few speciﬁc interactions between spIKK and cleft 2 (Fig. 3C). Notably,
however, the aliphatic staples replacing the side chain moieties of Q236 and E240
(though only partially ordered) pack alongside the aromatic side chain of F53 located
within the interface between clefts 1 and 2, where they form van Der Waals interac-
tions. The high level of conservation between ks-vFLIP–spIKK and ks-vFLIP–IKK(150–
272) extends beyond the ks-vFLIP binding region to the peptide-peptide interface,
which adopts a very similar composition and conﬁguration to the IKK dimer evident
in the complex with PDB code 3CL3 (Fig. 3C). This arises from the formation of a nearly
identical noncrystallographic dimer.
We next sought to assess the afﬁnity of spIKK for vFLIP using isothermal calorim-
etry (ITC). Owing to poor solubility in aqueous solutions, a competition assay was
performed in which IKK was titrated into GB1–ks-vFLIP preincubated with spIKK (Fig.
4A). In keeping with a high afﬁnity, the apparent dissociation constant (Kd) of the
vFLIP-IKK interaction in the presence of peptide increased approximately 80-fold, from
380 nM to 30 M. This corresponds to a Ki of 257 nM and is thus comparable to that
of IKK(150–272).
GST-IKK and spIKK inhibit ks-vFLIP-induced NF-B activation. Having estab-
lished that peptides can mimic IKK on the basis of our thermoﬂuor, structural, and ITC
studies, we next investigated their ability to attenuate NF-B activation. For cellular
expression, a GST–IKK–20-mer fusion protein (comprising the exact amino acid se-
quence of spIKK including the nonnative cysteine) was constructed, coexpressed with
ks-vFLIP in Jurkat cells, and probed for its capacity to disrupt assembly of the ks-vFLIP–
IKK complex (detected by immunoprecipitation using anti-IKK antibodies). Remark-
ably, the GST-peptide fusion protein virtually abolished formation of the ks-vFLIP–IKK
complex (Fig. 4B), demonstrating that peptides have the potential to severely attenuate
NF-B activation in cells. The ability of spIKK to inhibit the ks-vFLIP–IKK interaction in
cell extracts was next assessed by treating Jurkat cell lysates with spIKK for 1 h at 4°C,
followed by immunoprecipitation of IKK and detection of any associated ks-vFLIP (Fig.
4C). In parallel, IKK kinase activity in the immunoprecipitate (and hence NF-B activa-
tion) was also assessed by quantitatively measuring the levels of phosphorylation of
added recombinant IB (Fig. 4C). Our results revealed that the quantities of bound
ks-vFLIP detected were substantially reduced in lysates treated with peptide. This trend
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FIG 4 ITC experiments and the effects of IKK-mimetic peptides on NF-B activation. (A) (Top) ITC data obtained for the following: IKK titrated
into GB1–ks-vFLIP in which both proteins were dialyzed into deionized water (left), an analogous experiment but with the proteins dialyzed into
buffer (see Materials and Methods) (middle), and a competition assay in which spIKK was incubated with GB1–ks-vFLIP prior to titration of IKK
(performed in deionized water) (right). (Bottom) Table showing the corresponding “apparent” Kds and Ki for spIKK. (B) Immunoprecipitation
assays involving Jurkat cell lysates in which ks-vFLIP was expressed in the presence and absence of GST-IKK using anti-IKK antiserum (upper
(Continued on next page)
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was observed in the kinase assays, which surprisingly showed that in the presence of
spIKK, ks-vFLIP-induced activation is reduced back to background levels. Similar
results were also obtained when experiments were repeated with lysates from the PEL
cell line BC3, in which ks-vFLIP is endogenously expressed (Fig. 4D). Our ﬁndings
demonstrate that spIKK can dissociate preformed ks-vFLIP–IKK complexes, leading to
the near abolition of induced NF-B activation.
Both GST-IKK and spIKK promote PEL cell killing, particularly in the pres-
ence of TNF- and ETO. Given their profound impact on NF-B activation, we next
assessed whether IKK-mimetic peptides could sensitize BC3 cells to TNF- and ETO
and thus stimulate cell death. To investigate this in cellulo, BC3 cells were transduced
with the GST-IKK peptide vector prior to treatment with TNF- or ETO, and after 24 h,
their viabilities were assessed. As a control, similar trials were conducted but with
GST-IKKDM, which harbors the same peptide containing the F238R D242R IKK double
mutations previously shown to impair ks-vFLIP binding and consequently NF-B acti-
vation (27). The combination of GST-IKK and either TNF- or ETO signiﬁcantly reduced
cell viability compared to those with GST-IKKDM and GST (Fig. 5A), consistent with
removal of the ks-vFLIP-induced apoptotic block. We also determined whether spIKK
could have a similar effect. Owing to the presence of the aliphatic linker and overall
positive charge (0.1), we reasoned that spIKK was likely to be cell permeable based
on studies involving a diverse range of unrelated stapled peptides (28–32). BC3 cells
were therefore treated with spIKK either alone or in combination with TNF- or ETO
(Fig. 5B) and their viabilities assessed after 24 h. spIKK at the higher concentrations
tested caused a signiﬁcant reduction in their viability (50% inhibitory concentration
[IC50]  75 M after 24 h). Either TNF- or ETO caused a striking enhancement of
spIKK-induced BC3 cell death (Fig. 5B and C), but showed negligible effects individ-
ually. When viability was assessed at the later time of 48 h (Fig. 5C), cultures treated
with spIKK in the presence of either TNF- or ETO remained free of viable cells, while
in those treated with spIKK alone, viable cells remained. In contrast, similar experi-
ments conducted with DG75 cells (a PEL cell line negative for both KSHV and EBV [Fig.
5D]) showed no change in sensitivity to spIKK alone and when combined with either
TNF- or ETO. Considerable sensitivity to ETO, however, was detected after 48 h (Fig.
5E), consistent with its use as a therapeutic in the treatment of Burkitt’s lymphoma. The
effects of SPIKK were also investigated on BCP-1 cells, an additional PEL cell line.
Similar to results for BC3 cells, signiﬁcant killing was observed in the presence of
peptide alone, but when the peptide was combined with either ETO or TNF-, none
remained viable (Fig. 5F).
DISCUSSION
The canonical NF-B pathway is an essential transcriptional mechanism that is
hijacked by several viruses to prolong cellular survival and prevent apoptosis, thus
producing an environment conducive to viral propagation and ultimately proliferation.
Although it has been established that ks-vFLIP is required for protection against
apoptosis, in which it constitutively activates the pathway through physical association
with IKK, it was unclear whether there might also be coinvolvement of the DISC and/or
autophagy. Our studies reveal that this protection is mostly independent of both but,
interestingly, demonstrates marked differences between the viabilities of ETO-treated
Jurkat cells expressing ks-vFLIP in the ATG3 and FADD knockdowns and those treated
with TNF-. It has been reported that autophagy is a speciﬁc regulator of homologous
recombination (33). This, coupled with the fact that ETO functions by generating
FIG 4 Legend (Continued)
image) and normal rabbit serum (lower image). GST-IKK prevents the association of ks-vFLIP with IKK, evidenced by the absence of ks-vFLIP
from the pellet fraction. (C) (Top) Immunoprecipitation trials using Jurkat cell lysates treated with 50 M spIKK in which ks-vFLIP was absent or
overexpressed. (Bottom) Results of a kinase assay measuring the levels of phosphorylated IB in the presence and absence of spIKK. (D) Similar
to panel C except that immunoprecipitation assays were performed using BC3 cell lysates. The rabbit antiserum control is shown in the leftmost
image.
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FIG 5 Capacity of IKK-mimetic peptides to kill BC3 and BCP-1 cells in the presence and absence of TNF- and ETO. (A) Viability assays using BC3 cells
coexpressing GST-IKK (or GST-IKKDM harboring the F238A D242R double mutant, known to impair both vFLIP binding and NF-B activation) and
ks-vFLIP alone or following treatment with TNF- or ETO. (B) Viability assays in which BC3 cells expressing ks-vFLIP were treated with various
concentrations of spIKK in the presence and absence of TNF- or ETO at the speciﬁed concentrations. (C) Assays in which the viability of BC3 cells treated
with spIKK, TNF-, ETO, or combinations of spIKK and TNF- or ETO (at the speciﬁed concentrations) were monitored after 24 and 48 h. The curves for
spIKK plus TNF- (magenta) and spIKK plus ETO (yellow) overlap. (D) Effects of TNF- and ETO (at the speciﬁed concentrations) on the viability of DG75
cells at various concentrations of spIKK. (E) Control experiment illustrating the individual effects of spIKK, TNF-, and ETO together with the
spIKK-plus-TNF- and spIKK-plus-ETO combinations on the viability of DG75 cells (at the speciﬁed concentrations) at 24 and 48 h. While spIKK and
TNF- failed to have a negative impact (either alone or in combination), a signiﬁcant reduction in viability was observed for cells treated with ETO (or ETO
plus spIKK) at 48 h. (F) Viability assays conducted with BCP-1 cells similar to those for panel B but performed at the indicated concentrations of spIKK,
TNF-, and ETO.
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double-strand breaks, may explain why rescue, though signiﬁcant, is more limited in
this background. Since ETO is currently in use for the treatment of B cell malignancies,
our studies suggest avenues for future chemotherapeutic combinations.
Although the canonical NF-B pathway itself is an obvious target for the treatment
of PEL and other KS-associated malignancies, its requirement in processes such as
cellular differentiation, innate/adaptive immunity, and developmental switching (34)
make direct drug targeting likely to be associated with considerable toxicity. Given that
ks-vFLIP is virally encoded and signiﬁcantly distinct from its cellular cFLIP homologues
both structurally and functionally in terms of its mode of NF-B activation (18),
inhibitors aimed at targeting its interaction with IKK are unlikely to have these effects.
Here we demonstrate that spIKK, a conformationally constrained 20-mer helical
peptide comprising the IKK interacting element, or an equivalent GST-peptide fusion
protein (GST-IKK) can interact with ks-vFLIP and disrupt its association with IKK. Our
crystal structure of ks-vFLIP bound to spIKK reveals that its mode of interaction
directly mimics that of IKK in the original complex to the extent of forming a
heterotetrameric ks-vFLIP–spIKK assembly with conserved interactions in the spIKK-
spIKK interface. A high-afﬁnity interaction is further illustrated by ITC studies which
demonstrate that spIKK and IKK(150–272) have nearly equivalent binding afﬁnities.
We also show that spIKK and GST-IKK are potent attenuators of ks-vFLIP-induced
NF-B activation, illustrated by in vitro studies that include a kinase assay in which the
levels of phosphorylated IB following activation were assessed. Although the effects
of vFLIP stimulation appear to be minimal, we ﬁnd that the basal level of IKK activity in
many transformed cell lines is high and that the extent of vFLIP stimulation is corre-
spondingly small, though persistent (18). We have also found that more pronounced
effects are not observed when downstream events such as NF-B transcriptional
activity are alternatively assayed.
Although spIKK is able to directly instigate BCP-1 and BC3 cell killing, albeit at
moderate concentrations (IC50 75 M in BC3 cells, most likely as a consequence of
suboptimal permeability based on its comparable afﬁnity to IKK), both GST-IKK and
spIKK sensitize PEL to ETO and TNF- when ks-vFLIP is expressed.
While forming a useful tool compound, spIKK provides a template for the produc-
tion of high-afﬁnity therapeutic peptides given that no attempts were made to opti-
mize the sequence for maximal ks-vFLIP binding or cell permeability. Over the past
decade, the use of conformationally constrained helical peptides to target previously
intractable protein-protein interactions central to a diverse range of pathologies has
grown substantially owing to the ease with which they can be produced, their inherent
resistance to proteases, and the fact that they are expected to be well tolerated given
their more cognate nature (22, 35). In keeping with this, phase 1 clinical trials of a
long-acting growth hormone-releasing hormone agonist peptide for the potential
treatment of metabolic/endocrine diseases as well as HIV have so far been successful.
In addition to drug-based therapeutics, our studies further illustrate that it is possible
to mimic IKK using a GST-peptide fusion protein and thus provide an alternative
platform for the speciﬁc development of PEL- or KS-directed gene therapies.
MATERIALS AND METHODS
Cloning, protein expression, and puriﬁcation. (i) GB1-tagged ks-vFLIP. ks-vFLIP (residues 1 to
188) was PCR cloned into the EcoRI and XhoI sites of GB1-pBR22b (a modiﬁed pET22b vector containing
the streptococcal protein G immunoglobulin domain fusion tag [GB1], a kind gift from Paul Driscoll,
Francis Crick Institute) using the primers GB1vFLIP-Fwd and GB1vFLIP-Rev (Table 1). The resulting
plasmid, designed to generate a ks-vFLIP fusion protein with N- and C-terminal GB1 and 6His tags,
respectively (GB1-ks-vFLIP), was transformed into BL21(DE3) cells, for which single colonies were inoc-
ulated into LB medium (supplemented with 100 g ml1 of ampicillin) and grown overnight at 37°C.
These cultures were used to inoculate 2-liter ﬂasks containing 800 ml of 100-g ml1 ampicillin-
supplemented LB medium and grown to an optical density at 600 nm [OD600] of 0.6 to 0.8. The ﬂasks
were subsequently induced with 1 mM isopropyl--D-thiogalactopyranoside (IPTG), and the temperature
was reduced to 25°C overnight. The cultures were spun at 5,000  g for 20 min and pellets stored at
80°C or resuspended in lysis buffer (20 mM Tris-HCl [pH 8.5] and 200 mM NaCl [buffer A] plus 25 mM
imidazole) and subjected to two rounds of lysis using a Vibra cell sonicator. The resulting lysates were
spun at 46,000  g and supernatants passed through a 1.2-m ﬁlter prior to being loaded onto a 5-ml
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His-trap column preequilibrated in buffer A. The column was washed with 20 column volumes (CV) of
buffer A and GB1–ks-vFLIP eluted in buffer B (buffer A plus 500 mM imidazole) using a 5-CV step
gradient. The resulting protein was then concentrated in a 10-kDa-cutoff Vivaspin concentrator and
applied to a Superdex 26/60 S75 size exclusion column preequilibrated with buffer A supplemented with
250 mM imidazole and 5 mM dithiothreitol (DTT) {or 0.3 mM Tris(2-carboxyethylphosphine hydrochloride)
[TCEP]}. The eluted fractions were analyzed using SDS-PAGE, and those found to contain GB1–ks-vFLIP
at a purity of 95% were pooled, concentrated to 100 M using a 10-kDa-cutoff Vivaspin concentrator,
and stored at 4°C. Fractions used for crystallization trials were dialyzed into a buffer comprising 20 mM
Tris-HCl (pH 8.5), 50 mM glycine, and 10 mM TCEP-HCl prior to setup.
(ii) IKK(150–272) and ks-vFLIP(1–178). Details for the production and puriﬁcation of IKK(150–
272) and ks-vFLIP(1–178) have been previously reported by Bagnéris et al. (19).
(iii) Expression of GST fusion peptides. In order to express the IKK fusion peptides in Jurkat cells,
a GST fusion protein was produced by ﬁrst PCR amplifying the GST coding region of pGEX-4T1 using
Phusion high-ﬁdelity polymerase (New England BioLabs [NEB]) and the primers GST-Fwd and GST-Rev
(Table 1). The PCR product was then cloned into a pJET-C1 vector (Fermentas). Following digestion of
pJET-C1-GST with BglII and SalI to release the GST coding sequence, the GST product was cloned into the
pDual-Cherry lentiviral vector (36) downstream of the spleen focus-forming virus (SFFV) promoter using
the BglII/SalI sites. The resulting construct incorporated BamHI and SalI sites at the C terminus of GST that
were used for insertion of the peptides. To produce the GST-IKK and GST-IKKDM constructs, IKK
wild-type peptide primers (GST-IKK-Fwd and GST-IKK-Rev [Table 1]) corresponding to the spIKK
protein sequence (residues 230 to 248, including a nonnative C-terminal cysteine) or the same sequence
modiﬁed to incorporate the F238R D242R double mutant (GST-IKKDM-Fwd and GST-IKKDM-Rev),
shown to drastically impair ks-vFLIP binding (27), were subsequently annealed at 95°C for 10 min before
being ligated into the pDUAL-GST vector following digestion of the vector with BamHI and SalI.
Lentiviral vectors expressing GST or GST fusion peptides together with green ﬂuorescent protein
(GFP), CherryFP, WT vFLIP, or vFLIPA57L (a mutant which fails to bind IKK) were produced as previously
described (19). These were used to transfect unmodiﬁed Jurkat cells, those lacking IKK (37), those in
which ATG3 or FADD was downregulated using a combination of two siRNAs for each mRNA (17) (target
sequences provided in Table 1), and also the human B cell line BC3 (a PEL cell line harboring KSHV). In
each case, lentiviral vector doses were used to ensure that over 95% of cells were positive for the relevant
ﬂuorescent protein. The anti-FADD antibody used for immunoblots was purchased from BD Biosciences,
and those for anti-ATG3 and anti-glyceraldehyde-3-phosphate dehydrogenase (anti-GAPDH) were from
Cell Signaling Technology. Jurkat cells and their IKK-null derivatives were obtained from Alain Israel,
Institute Pasteur, and veriﬁed as human T cells by surface CD3 staining.
BC3, BCP-1, and DG75 cells were purchased for this study from the American Type Culture Collection
(ATCC). They were veriﬁed as human B cell lines by surface staining for human Ig.
Cell viability assays. The transfected cells, the human B cell lines BC3, BCP-1, and DG75 (a PEL cell
line negative for KSHV and Epstein-Barr virus [EBV]) were treated with human TNF- (PeproTech or
Alomone Labs), ETO (Sigma), spIKK (encompassing IKK residues 230 to 248; see Fig. 3 for structure), or
combinations of spIKK with either TNF- or ETO. Cell survival was determined after 24 and 48 h by
trypan blue staining and counting with a hemocytometer. Cell viability is expressed as a percentage of
the number of viable cells per culture at the start of each experiment. Results show the means and
standard deviations of triplicate independent experiments. Signiﬁcance difference was calculated by
two-way analysis of variance (ANOVA) with Fisher’s least signiﬁcant difference (LSD) posttest.
Thermoﬂuor assays. Thermoﬂuor studies were conducted using the MyIQ reverse transcription-PCR
(RT-PCR) system (Bio-Rad) in a 96-well plate format. Trials were performed in which 30 M ks-vFLIP
(unless otherwise stated) was combined with either IKK or mimetic peptides (at the speciﬁed concen-
trations) prior to the addition of SYPRO orange diluted in a 1:1,000 (vol/vol) ratio and thermal denatur-
ation. The data were subsequently processed using the Bio-Rad iQ5 software. Each experiment was
repeated at least 3 times. All peptides were purchased from Eurogentec.
TABLE 1 List of all primers used to produce the various plasmid constructs detailed together with target sequences for the FADD and
ATG3 siRNAsa
Primer or target Sequence
GB1vFLIP-Fwd TTgaattcGATGGCCACTTACG
GB1vFLIP-Rev AActcgagCGCCTATGGTG
GST Fwd agatctGCCACCATGTCCCCTATACTAGGTTATTGG
GST Rev gtcgacctactactaggatccACGCGGAACCAGACCACCACC
GST-IKK-Fwd gatccTTGCAGGTGGCCTATCACCAGCTCTTCCAAGAATACGACAACCACATCAAGAGCAGCGTGGTGGGCAGTtag
GST-IKK-Rev tcgactaACTGCCCACCACGCTGCTCTTGATGTGGTTGTCGTATTCTTGGAAGAGCTGGTGATAGGCCACCTGCAAg
GST-IKKDM-Fwd gatccTTGCAGGTGGCCTATCACCAGCTCcgCCAAGAATACcgCAACCACATCAAGAGCAGCGTGGTGGGCAGTtag
GST-IKKDM-Rev tcgactaACTGCCCACCACGCTGCTCTTGATGTGGTTGcgGTATTCTTGGcgGAGCTGGTGATAGGCCACCTGCAAg
FADD target 1 CATGGAACTCAGACGCATCTA
FADD target 2 TGAACTCAAGCTGCGTTTATT
ATG3 target 1 CCAGAACTTATGACCTTTACA
ATG3 target 2 ATGTGACCATTGACCATATTT
aThe restriction sites, stop codons, and positions mutated in the IKK double mutant GST constructs (GST-IKKDM-Fwd and GST-IKKDM-Rev) are shown in lowercase
and are underlined.
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Crystallization and structure determination of the GB1–ks-vFLIP–spIKK complex. spIKK
(Eurogentec) was ﬁrst dissolved in 100% dimethyl sulfoxide (DMSO) to a concentration of 2 mM. A 1:1
ratio of GB1–ks-vFLIP to spIKK was next combined to give a ﬁnal GB1–ks-vFLIP concentration of 50 to
70 M. A Mosquito crystallization robot was used to set up vapor diffusion crystallization trials involving
a range of commercially available screens. Drops of 200 nl (ﬁnal volume) were dispensed in a 1:1 ratio
of complex to well solution, and after 1 week, small crystals were observed under the condition 1.2 M
ammonium sulfate, 0.05 M trisodium citrate, and 3% isopropanol. In attempts to improve their size and
diffraction quality, the Silver Bullet additive screen (Hampton Research) was used in conjunction with the
above-described condition. Of the various additives, vitamin B12 produced the most signiﬁcant improve-
ments and was subsequently included in repeat trials of the original condition at a concentration of 0.1
to 0.2%.
Crystals of the GB1–ks-vFLIP–spIKK complex, grown in the presence of vitamin B12, were cryopro-
tected in 25 to 30% glycerol and ﬂash frozen in liquid nitrogen prior to irradiation at SOLEIL on the
Proxima 1 beamline. Data were collected to a maximum resolution of 3.3 Å on two crystals that were
integrated and scaled using XDS (38). The data sets were merged and truncated using AIMLESS (CCP4
[39, 40]) in space group P63. At this stage, the data were found to be signiﬁcantly anisotropic, which was
subsequently corrected for using STARANISO (Global Phasing [http://staraniso.globalphasing.org/cgi
-bin/staraniso.cgi]). The effective resolution of the corrected data was reduced to 3.38 Å (giving an overall
completeness of95% [Table 2]). The structure was determined using molecular replacement in PHASER
(41) where two GB1–ks-vFLIP monomers were identiﬁed in the asymmetric unit. Clear density for
peptides associated with each monomer could be observed in the IKK binding sites, which were
subsequently modeled using COOT (42), along with those of the GB1 monomers which were compar-
atively poorly ordered. Although side chains could be identiﬁed for the majority of residues within each
of the spIKK peptides, the aliphatic staples were only partially ordered. Reﬁnement was performed
using AUTOBUSTER (43), which incorporated noncrystallographic symmetry (NCS) restraints together
with translation, libration, screw (TLS) reﬁnement, interspersed with manual rebuilding. Data collection
statistics and those for the reﬁned model can be found in Table 2 and are within the expected ranges
for a structure at this resolution.
ITC. Isothermal calorimetry (ITC) experiments were performed using a Microcal VP-ITC micocalorim-
eter (MicroCal). For all binding reactions, syringe concentrations varied between 85 and 100 M for
TABLE 2 Data collection, processing, and reﬁnement statistics
Parameter Value(s)a
Data collection statistics
Space group P63
Unit cell [a, b, c (Å)] a  b  90.48, c  134.75,
    90,   120
Resolution (Å) 78.5–3.3 (3.3–3.6)
Total no. of reﬂections 89,313
No. of unique reﬂections 9,482
Redundancy 9.4 (9.6)
Completeness (%) 99.80 (99.7)
	I
/	(I)
 10.3 (1.3)
Rmeasb 0.11 (1.8)
Reﬁnement (STARANISO-corrected data)
Resolution (Å) 25–3.4 (3.4–3.8)
No. of protein/peptide atoms 3,437
Completeness (%) 95.7 (85.2)
Rworkc/Rfreed (%) 25.7/29.0
Estimated coordinate error based on Rfree (Å) 0.61
Mean B-factor (Å2) 135
Deviations from ideal stereochemistry
RMSD bonds (Å) 0.009
RMSD angles (°) 1.03
Wilson B-factor (Å2) 115
Ramachandran plot analysise
Most favored (%) 95.6
Additionally allowed (%) 2.64
Disallowed (%) 1.76
aValues in parentheses are for the highest-resolution shell (3.4–3.8 Å).
bRmeas  [(N/N  1)]1/2[(|Ii  	I
|)/(	I
)], where the sum is calculated over all observations of a measured
reﬂection (Ii), 	I
 is the mean intensity of all the measured observations (Ii), and N is the total number of
observations for each reﬂection.
cRwork   (|Fobs  Fcalc|)/ (Fobs), where Fobs is the observed structure factor amplitude and Fcalc those
calculated from the model.
dRfree is equivalent to Rwork but where 5% of the measured reﬂections have been excluded from reﬁnement
and set aside for cross-validation purposes.
eRamachandran plot analysis was from molprobity (http://molprobity.biochem.duke.edu/).
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IKK(150–272) and cell concentrations between 8 and 10 M for GB1-vFLIP. Titrations consisted of an
initial 2-l injection, followed by 20 10-l injections with stirring at 300 rpm. In competition assays,
GB1–ks-vFLIP was ﬁrst incubated with 20 M spIKK and DMSO to 4% prior to loading into the cell and
titration with IKK(150–272). All ITC binding experiments were performed in deionized water at 25°C
owing to the buffer constraints of spIKK, GB1–ks-vFLIP, and IKK(150–272), where GB1–ks-vFLIP and
IKK(150–272) were buffer matched by overnight dialysis, followed by the addition of 4% DMSO to each.
It was conﬁrmed that the use of deionized water and 4% DMSO had no discernible impact on structural
integrity and/or the afﬁnity of IKK(150–272) for GB1–ks-vFLIP by parallel ITC experiments in which both
proteins were alternatively dialyzed into a buffer comprising 20 mM Tris-HCl (pH 8.5), 200 mM NaCl, and
0.3 mM TCEP. Kd values comparable to those obtained using deionized water were observed (see “SpIKK
is an effective mimetic of IKK” above and Fig. 4). Following collection, all data were analyzed using
ORIGIN 70 software and ﬁtted to a one-site binding model with each experiment performed at least in
triplicate.
Cell-based immunoprecipitation assays. To probe the ks-vFLIP–IKK interaction, Jurkat or BC3 cells
were lysed and immunoprecipitation was performed using an anti-IKK antibody (FL-419; Santa Cruz
Biotechnology) or normal rabbit serum as a control. Lysates and immunoprecipitates were blotted using
anti-ks-vFLIP antibodies (6). In vitro IKK kinase assays were performed as previously described (17).
Accession number(s). The coordinates determined in this study have been deposited at the Protein
Data Bank under accession code 5LDE.
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